Five Widely Used Cancer Treatments in the U.S.

Surgery: The Foundation for Many Solid Tumors

For many solid tumors found at an early stage, surgery is the backbone of treatment and, in some cases, the primary path to cure. Surgeons aim to remove the visible tumor with a margin of healthy tissue, sometimes along with nearby lymph nodes to check for spread. Techniques have diversified: in addition to traditional open operations, minimally invasive methods and robot-assisted procedures can reduce incision size, blood loss, and hospital stay. The core principle is the same—remove what should not be there while preserving function and quality of life.

Evidence from national registries shows why surgery remains so central. When cancers are localized, outcomes often improve dramatically after complete resection. For example, early-stage colon or kidney cancers can be controlled successfully with surgical removal, and certain breast cancers treated with lumpectomy plus radiation achieve long-term results comparable to more extensive operations. In some cases, surgery is paired with treatment before or after the operation (called neoadjuvant or adjuvant therapy) to shrink the tumor, lower the risk of recurrence, or address microscopic disease.

Decisions about surgery consider anatomy, tumor biology, and the person’s overall health. A multidisciplinary tumor board—typically including surgeons, medical oncologists, and radiation oncologists—reviews imaging and pathology to recommend a coherent plan. If an operation could affect vital functions—speech, swallowing, fertility, or mobility—teams increasingly use nerve-sparing strategies, reconstructive techniques, and rehabilitation services to protect daily life. Sometimes, the most patient-centered choice is to delay or avoid surgery in favor of systemic therapy first, especially when imaging suggests a better response after initial drug treatment.

Key points patients often weigh:
– Potential goals: cure, long-term control, or symptom relief
– Expected benefits vs. risks: bleeding, infection, pain, anesthesia concerns
– Recovery timeline: hospital stay, wound care, return to work and activities
– Effects on function: strength, range of motion, appearance, and sensation

Practical tip: ask how the surgical plan will be evaluated for success—clean margins on pathology, restored function targets, and the schedule for follow-up imaging. Understanding what “good” looks like ahead of time makes each post-op milestone clearer.

Radiation Therapy: Precision Beams That Treat What the Eye Cannot See

Radiation therapy uses high-energy beams to damage the DNA of cancer cells, stopping their ability to grow. About half of people with cancer in the U.S. receive radiation at some point, either alone or in combination with other treatments. External beam radiation is the most common method, delivered from a machine that rotates around the body, shaping the dose with remarkable accuracy. Internal radiation (brachytherapy) places radioactive sources within or near the tumor, allowing a high dose to the target while sparing nearby tissues. Specialized techniques such as stereotactic treatments and proton therapy further refine how dose is deposited, particularly when sensitive organs are close by.

The planning process is meticulous. A simulation session involves imaging—often CT or MRI—to map the tumor and surrounding anatomy. Radiation oncologists draw “target volumes” and identify structures to avoid, while physicists design beam angles and intensities to confine energy where it is needed. Treatments are typically delivered over days or weeks in short sessions, which are painless and quick. Because cancer cells and normal cells repair damage differently, fractionating the total dose into multiple sessions gives normal tissues time to heal.

Side effects depend on the site treated and total dose. For head and neck regions, people may experience dry mouth or changes in taste; for pelvic fields, bowel and bladder irritation can occur; for chest tumors, temporary fatigue or skin redness is common. Most effects are manageable and improve after therapy, though a small proportion can be longer lasting. Teams often use supportive measures—skin care regimens, dietary counseling, saliva substitutes, pelvic floor therapy—to minimize discomfort and protect function.

Radiation’s roles include:
– Curative treatment for localized cancers when surgery is not ideal
– Organ preservation (for example, larynx or prostate) while maintaining control
– Adjuvant use after surgery to reduce recurrence risk in high-risk settings
– Palliation to ease pain, bleeding, or pressure from metastases

Comparisons matter. For some breast and prostate cancers, radiation-based approaches offer outcomes comparable to surgery with different trade-offs in side effects and convenience. Conversely, certain sarcomas or kidney tumors are more often managed surgically, with radiation reserved for specific scenarios. Asking about the likelihood of local control, the chance of needing additional therapy later, and the expected impact on everyday routines can help align treatment with personal priorities.

Chemotherapy: Systemic Treatment That Reaches Beyond the Scan

Chemotherapy uses medicines that travel through the bloodstream to attack rapidly dividing cells. It remains a mainstay for many cancers because it can treat disease that is too small to see on imaging or that has already spread. Regimens vary by cancer type and stage, often combining several drugs to target cells at different points in the growth cycle. Sometimes chemotherapy is used before surgery or radiation to shrink a tumor and improve the chance of complete removal; other times it is given afterward to reduce the risk of recurrence by sweeping up microscopic cells.

Clinical practice has grown more precise. Teams tailor doses to kidney and liver function, overall health, and personal goals. Advances in anti-nausea strategies, growth factor support, and infection prevention have made modern chemotherapy more manageable than many people expect. That said, side effects still require planning. Short-term issues can include fatigue, hair loss, appetite changes, and increased infection risk due to low white blood cells. Some drugs can affect the heart, kidneys, or nerves; oncology teams monitor closely with labs and exams, adjusting doses as needed.

When considering chemotherapy, patients and clinicians weigh:
– The absolute benefit: added months or years of disease control or cure probability
– The schedule and logistics: infusion center visits vs. oral options, cycle length, lab checks
– Quality of life: expected side effects, supportive medicines, work and family responsibilities
– Exit ramps: criteria for pausing, reducing, or changing therapy if goals are not met

Comparatively, chemotherapy is less targeted than modern precision medicines, but it remains indispensable. In some leukemias, lymphomas, and testicular cancers, chemotherapy can achieve high cure rates. In metastatic disease, it often prolongs life and relieves symptoms, even when cure is not possible. Increasingly, chemotherapy is combined with targeted drugs or immunotherapies to improve outcomes, reflecting a shift from single-modality care to thoughtfully sequenced combinations. The conversation is not “chemotherapy or nothing,” but rather “how does chemotherapy fit into a plan that balances benefit and burden for me?”

Targeted Therapy: Precision Medicines Guided by Biomarkers

Targeted therapy focuses on vulnerabilities created by specific genetic alterations or protein signals that drive a cancer’s growth. Instead of broadly attacking fast-dividing cells, these drugs aim at pathways cancers rely on, such as those linked to alterations in EGFR, ALK, BRAF, HER2, PARP-related DNA repair, and more. The crucial first step is comprehensive testing of the tumor (and sometimes blood) to look for actionable biomarkers. When a match is found, targeted agents can deliver meaningful responses with side effect profiles that often differ from traditional chemotherapy.

What does “targeted” mean in day-to-day terms? In lung cancers with certain driver mutations, oral inhibitors may shrink tumors quickly and produce symptom relief within weeks. In breast cancers with specific receptor overexpression, antibody-based therapies can zero in on malignant cells while sparing most normal tissues. In some leukemias, inhibitors of abnormal kinases have transformed long-term disease control. However, resistance can emerge—cancer cells evolve, find workarounds, or acquire new mutations—so follow-up scans, blood tests, and sometimes repeat biopsies help teams pivot to next-line options.

Considerations to discuss with your clinician:
– Testing scope: is broad panel sequencing indicated, and will it be repeated at progression?
– Benefit profile: typical response rates, time to response, and median duration of control for your biomarker
– Side effects: diarrhea, skin rash, blood pressure changes, liver enzyme elevations, or cardiac monitoring needs
– Access and adherence: oral dosing schedules, drug-drug interactions, and travel or lab logistics

Compared with chemotherapy, targeted therapy can be more selective, which may reduce certain side effects while introducing others linked to the pathway being inhibited. Real-world studies show that patients with a true biomarker match often experience higher response rates than with non-matched regimens. Still, not every tumor carries an actionable alteration, and even responsive cancers may eventually progress. That is why many centers integrate targeted drugs into combination strategies, pairing them with surgery, radiation, or immunotherapy when evidence suggests added benefit. The overarching theme is personalization—letting the biology lead the way while staying ready to adapt as the biology changes.

Immunotherapy and Cellular Therapy: Training the Body to Recognize Cancer

Immunotherapy seeks to help the immune system see and attack cancer. The most widely used approach in the U.S. involves checkpoint inhibitors—antibodies that block inhibitory signals such as PD-1 or PD-L1, or activate pathways like CTLA-4 blockade—so T cells can engage tumors more effectively. For some people, responses can be deep and long-lasting, even after treatment stops. Response rates vary widely by cancer type and biomarker status; tumors with features such as high PD-L1 expression, mismatch repair deficiency, or high tumor mutational burden tend to respond more often.

Cellular therapies, including engineered T cells designed to recognize cancer-specific markers, have changed the landscape for certain blood cancers. In these settings, remission rates can be high when other treatments have failed. The logistics are complex—cells are collected, modified outside the body, and reinfused—so eligibility depends on disease status, organ function, and access to specialized centers. While expansion continues, this approach is currently used for select leukemias, lymphomas, and related conditions, with research rapidly exploring new targets and ways to broaden availability.

Important points to explore with your team:
– Likelihood of benefit in your cancer type and biomarker profile
– Potential side effects: immune-related inflammation affecting skin, colon, lungs, liver, or endocrine glands
– Monitoring plan: prompt reporting of new symptoms is critical, as early steroids can reverse many effects
– Durability vs. speed: some responses build over weeks; others, particularly with cellular therapy, can be swift

Compared with chemotherapy, immunotherapy can feel like flipping a hidden switch rather than pushing directly on the tumor. Yet it is not a universal key: a meaningful subset of patients do not respond, and some experience serious immune reactions that require careful management. Combinations—adding immunotherapy to chemotherapy or targeted agents—can increase the chance of response in certain cancers, though with added toxicity. The goal is to identify people most likely to benefit and to intervene early if side effects appear. Clinical trials remain a vital pathway to next-generation strategies, including personalized vaccines and combinations designed to overcome resistance.